Literature DB >> 24833862

Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities.

Mina Shaker1, Adam Tabbaa1, Mazen Albeldawi1, Naim Alkhouri1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is becoming rapidly one of the most common indications for orthotopic liver transplantation in the world. Development of graft steatosis is a significant problem during the post-transplant course, which may happen as a recurrence of pre-existing disease or de novo NAFLD. There are different risk factors that might play a role in development of graft steatosis including post-transplant metabolic syndrome, immune-suppressive medications, genetics and others. There are few studies that assessed the effects of NAFLD on graft and patient survival; most of them were limited by the duration of follow up or by the number of patients. With this review article we will try to shed light on post-liver transplantation NAFLD, significance of the disease, how it develops, risk factors, clinical course and treatment options.

Entities:  

Keywords:  Liver cirrhosis; Liver transplantation; Metabolic syndrome; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis

Mesh:

Year:  2014        PMID: 24833862      PMCID: PMC4017047          DOI: 10.3748/wjg.v20.i18.5320

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  100 in total

1.  Liver transplantation for cirrhosis following jejuno-ileal bypass--regional cytokine differences associated with pathological changes in the transplant liver.

Authors:  G W Burke; R Cirocco; G Hensley; D Ranjan; R Reddy; L Jeffers; E Schiff; J Miller
Journal:  Transplantation       Date:  1992-08       Impact factor: 4.939

Review 2.  Hypertension after liver transplantation.

Authors:  S C Textor; V J Canzanello; S J Taler; L Schwartz; J Augustine
Journal:  Liver Transpl Surg       Date:  1995-09

3.  Adiponutrin, a transmembrane protein corresponding to a novel dietary- and obesity-linked mRNA specifically expressed in the adipose lineage.

Authors:  S Baulande; F Lasnier; M Lucas; J Pairault
Journal:  J Biol Chem       Date:  2001-06-28       Impact factor: 5.157

4.  Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.

Authors:  Alexander J Thompson; Andrew J Muir; Mark S Sulkowski; Dongliang Ge; Jacques Fellay; Kevin V Shianna; Thomas Urban; Nezam H Afdhal; Ira M Jacobson; Rafael Esteban; Fred Poordad; Eric J Lawitz; Jonathan McCone; Mitchell L Shiffman; Greg W Galler; William M Lee; Robert Reindollar; John W King; Paul Y Kwo; Reem H Ghalib; Bradley Freilich; Lisa M Nyberg; Stefan Zeuzem; Thierry Poynard; David M Vock; Karen S Pieper; Keyur Patel; Hans L Tillmann; Stephanie Noviello; Kenneth Koury; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; David B Goldstein; John G McHutchison
Journal:  Gastroenterology       Date:  2010-04-24       Impact factor: 22.682

5.  Recurrence of nonalcoholic steatohepatitis following liver transplantation.

Authors:  W R Kim; J J Poterucha; M K Porayko; E R Dickson; J L Steers; R H Wiesner
Journal:  Transplantation       Date:  1996-12-27       Impact factor: 4.939

Review 6.  Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease.

Authors:  Silvia Sookoian; Carlos J Pirola
Journal:  Hepatology       Date:  2011-05-14       Impact factor: 17.425

7.  Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus.

Authors:  M D Stegall; M E Wachs; G Everson; T Steinberg; B Bilir; R Shrestha; F Karrer; I Kam
Journal:  Transplantation       Date:  1997-12-27       Impact factor: 4.939

8.  Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis.

Authors:  Shahid M Malik; Michael E Devera; Paulo Fontes; Obaid Shaikh; Eizaburo Sasatomi; Jawad Ahmad
Journal:  Liver Transpl       Date:  2009-12       Impact factor: 5.799

9.  Weight change and obesity after liver transplantation: incidence and risk factors.

Authors:  J E Everhart; M Lombardero; J R Lake; R H Wiesner; R K Zetterman; J H Hoofnagle
Journal:  Liver Transpl Surg       Date:  1998-07

10.  Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.

Authors:  Sunder Mudaliar; Robert R Henry; Arun J Sanyal; Linda Morrow; Hanns-Ulrich Marschall; Mark Kipnes; Luciano Adorini; Cathi I Sciacca; Paul Clopton; Erin Castelloe; Paul Dillon; Mark Pruzanski; David Shapiro
Journal:  Gastroenterology       Date:  2013-05-30       Impact factor: 22.682

View more
  32 in total

1.  S-allylmercaptocysteine improves nonalcoholic steatohepatitis by enhancing AHR/NRF2-mediated drug metabolising enzymes and reducing NF-κB/IκBα and NLRP3/6-mediated inflammation.

Authors:  Qian Yu; Yann-Yin Lee; Zheng-Yun Xia; Emily C Liong; Jia Xiao; George L Tipoe
Journal:  Eur J Nutr       Date:  2020-06-17       Impact factor: 5.614

2.  Development of a classification model for non-alcoholic steatohepatitis (NASH) using confocal Raman micro-spectroscopy.

Authors:  Jie Yan; Yang Yu; Jeon Woong Kang; Zhi Yang Tam; Shuoyu Xu; Eliza Li Shan Fong; Surya Pratap Singh; Ziwei Song; Lisa Tucker-Kellogg; Peter T C So; Hanry Yu
Journal:  J Biophotonics       Date:  2017-06-21       Impact factor: 3.207

Review 3.  New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.

Authors:  Natalia Pydyn; Katarzyna Miękus; Jolanta Jura; Jerzy Kotlinowski
Journal:  Pharmacol Rep       Date:  2020-01-08       Impact factor: 3.024

Review 4.  Metabolic complications in liver transplant recipients.

Authors:  Miguel Jiménez-Pérez; Rocío González-Grande; Edith Omonte Guzmán; Víctor Amo Trillo; Juan Miguel Rodrigo López
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

5.  Lack of Multidrug Resistance-associated Protein 4 Prolongs Partial Hepatectomy-induced Hepatic Steatosis.

Authors:  Ajay C Donepudi; Gregory J Smith; Oladimeji Aladelokun; Yoojin Lee; Steven J Toro; Marisa Pfohl; Angela L Slitt; Li Wang; Ji-Young Lee; John D Schuetz; José E Manautou
Journal:  Toxicol Sci       Date:  2020-06-01       Impact factor: 4.849

Review 6.  Nonalcoholic Fatty Liver Disease Among Individuals with HIV Mono-infection: A Growing Concern?

Authors:  Margaret Morrison; Heather Y Hughes; Susanna Naggie; Wing-Kin Syn
Journal:  Dig Dis Sci       Date:  2019-10-23       Impact factor: 3.199

7.  Using zebrafish to model liver diseases-Where do we stand?

Authors:  Duc-Hung Pham; Changwen Zhang; Chunyue Yin
Journal:  Curr Pathobiol Rep       Date:  2017-05-03

8.  The Main Thing is to be Alive-Exploring Patients' Experiences With Weight Gain After Liver Transplantation: A Qualitative Study.

Authors:  Sonja Beckmann; Patrizia Künzler-Heule; Kajetan Kabut; Oliver Mauthner
Journal:  Transpl Int       Date:  2022-04-14       Impact factor: 3.842

9.  Hepatoprotective Role of Eclipta alba against High Fatty Diet Treated Experimental Models - A Histopathological Study.

Authors:  K Satheesh Naik; M Gurushanthaiah; M Kavimani; K Prabhu; S Lokanadham
Journal:  Maedica (Bucur)       Date:  2018-09

10.  Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis.

Authors:  Chongshu Jian; Jiajun Fu; Xu Cheng; Li-Jun Shen; Yan-Xiao Ji; Xiaoming Wang; Shan Pan; Han Tian; Song Tian; Rufang Liao; Kehan Song; Hai-Ping Wang; Xin Zhang; Yibin Wang; Zan Huang; Zhi-Gang She; Xiao-Jing Zhang; Lihua Zhu; Hongliang Li
Journal:  Cell Metab       Date:  2020-05-05       Impact factor: 31.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.